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Articles
The relationship between cortical glutamate and striatal 
dopamine in first-episode psychosis: a cross-sectional 
multimodal PET and magnetic resonance spectroscopy 
imaging study
Sameer Jauhar*, Robert McCutcheon*, Faith Borgan, Mattia Veronese, Matthew Nour, Fiona Pepper, M Rogdaki, James Stone, Alice Egerton, 
Frederico Turkheimer, Philip McGuire, Oliver D Howes
Summary
Background The pathophysiology of psychosis is incompletely understood. Disruption in cortical glutamatergic 
signalling causing aberrant striatal dopamine synthesis capacity is a proposed model for psychosis, but has not been 
tested in vivo. We therefore aimed to test the relationship between cortical glutamate concentrations and striatal 
dopamine synthesis capacity, and psychotic symptoms.
Methods In this cross-sectional multimodal imaging study, 28 individuals with first-episode psychosis and 20 healthy 
controls underwent ¹⁸F-DOPA PET (measuring striatal dopamine synthesis capacity), and proton magnetic resonance 
spectroscopy (measuring anterior cingulate cortex glutamate concentrations). Participants were recruited from first-
episode psychosis services in London, UK and were required to be in the first episode of a psychotic illness, with no 
previous illness or treatment episodes. Exclusion criteria for all participants were: history of substantial head trauma, 
dependence on illicit substances, medical comorbidity (other than minor illnesses), and contraindications to scanning 
(such as pregnancy). Symptoms were measured using the Positive and Negative Syndrome Scale. The primary 
endpoint was the relationship between anterior cingulate cortex glutamate concentrations and striatal dopamine 
synthesis capacity in individuals with their first episode of psychosis as shown by imaging, examined by linear 
regression. Linear regression was used to examine relationships between measures.
Findings Glutamate concentrations showed a significant inverse relationship with striatal dopamine synthesis 
capacity in patients with psychosis (R²=0∙16, p=0∙03, β −1·71 × 10–⁴, SE 0∙76 × 10–⁴). This relationship remained 
significant after the addition of age, gender, ethnicity, and medication status to the model (p=0∙015). In healthy 
controls, there was no significant relationship between dopamine and glutamate measures (R²=0∙04, p=0∙39). 
Positive and Negative Syndrome Scale positive psychotic symptoms were positively associated with striatal dopamine 
synthesis capacity (R²=0∙14, p=0∙046, β 2546, SE 1217) and showed an inverse relationship with anterior cingulate 
glutamate concentrations (R²=0∙16, p=0∙03, β −1∙71 × 10−⁴, SE 7∙63 × 10−⁵). No relationships were seen with negative 
symptoms (positive symptoms, mean [SD] −18∙4 (6∙6) negative symptoms, mean [SD] −15∙4 [6∙1]).
Interpretation These observations are consistent with the hypothesis that cortical glutamate dysfunction is related to 
subcortical dopamine synthesis capacity and psychosis. Although the precise mechanistic relationship between 
cortical glutamate and dopamine in vivo remains unclear, our findings support further studies to test the effect of 
modulating cortical glutamate in the treatment of psychosis.
Funding Medical Research Council, Wellcome Trust, Biomedical Research Council, South London and Maudsley 
NHS Foundation Trust, JMAS Sim Fellowship, Royal College of Physicians (Edinburgh) (SJ).
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The dopamine hypothesis of schizophrenia has been one 
of the most enduring scientific hypotheses within 
psychiatry. From its origins in the mode of action of 
antipsychotic drugs, this hypothesis has evolved into a 
more nuanced model of dopamine dysregulation leading 
to psychosis.1 Theories have incorporated the effect of 
various genetic and environmental factors on this system, 
and suggest that glutamatergic dysfunction might underlie 
striatal dopamine dysregulation at onset of psychosis.2 
Meta-analytic data from in-vivo molecular imaging (single-
photon-emission tomography, single-photon-emission CT, 
and PET) studies have shown dopamine synthesis capacity 
is greater in individuals with schizophrenia than in health 
controls, with an effect size of around 0∙7.3 Dopamine 
synthesis capacity has also been found to be directly 
correlated with symptoms in some studies of people at 
ultra-high risk4 and with established psychosis.5
Previous studies using proton magnetic resonance 
spectroscopy (MRS) to measure brain glutamate 
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concentrations in schizophrenia have produced mixed 
findings, which could reflect effects of age, illness stage, 
or antipsychotic medication. Studies reporting glutamate 
concentrations (as opposed to glutamine, or the sum of 
glutamine and glutamate, termed Glx) in the frontal 
cortex are equivocal.6 When the relationship between 
glutamate concentrations and symptom severity has 
been examined, no consensus has been found, with both 
positive and negative correlations reported.7
Glutamatergic projections to the midbrain play a major 
role in regulating activity of mesostriatal dopamine 
neurons.8 Direct pathways from the prefrontal cortex to 
the midbrain have an excitatory influence and enhance 
dopamine release, whereas indirect pathways involving 
GABAergic interneurons have the opposite effect.9 If 
direct pathways predominate, then lower glutamatergic 
signalling is expected to lead to lower striatal dopaminergic 
signalling, whereas if indirect pathways dominate, then 
lower glutamatergic signalling will disinhibit mesostriatal 
dopamine neurons, resulting in greater dopaminergic 
signalling. The possibility that the second of these 
mechanisms predominates was raised by an in-vivo study 
in healthy controls, which found an inverse correlation 
between glutamate in the dorsolateral prefrontal cortex 
and striatal dopamine synthesis capacity.10
It has been proposed that in individuals with 
schizophrenia, glutamatergic dysfunction in the frontal 
cortex leads to negative and cognitive symptoms, and, via 
projections to the midbrain, disinhibits mesostriatal 
dopamine neurons, resulting in positive psychotic 
symptoms.2 However, to our knowledge, no study has 
investigated whether striatal dopamine synthesis capacity 
and cortical glutamate concentrations are correlated in 
people with psychosis, or if this correlation is related to 
symptoms.
In this study, we estimated anterior cingulate cortex 
glutamate concentrations, using proton MRS, and striatal 
dopamine, using ¹⁸F-DOPA PET, in individuals presenting 
with their first episode of psychosis. We hypothesised that 
anterior cingulate glutamate concentrations would be 
inversely correlated with striatal dopamine synthesis 
capacity, and that the severity of psychotic symptoms 
would correlate directly with dopamine synthesis capacity, 
and inversely with glutamate concentrations.
Methods
Participants
Participants were recruited from first-episode psychosis 
services in London, UK and were required to be in the 
first episode of a psychotic illness, with no previous 
illness or treatment episodes. Participants had to have a 
diagnosis of a psychotic disorder meeting ICD-10 criteria11 
and to have experienced psychotic symptoms, defined as 
a rating of at least moderate severity on one or more of 
the delusion, hallucination, and persecution items on the 
Positive and Negative Syndrome Scale (PANSS).12 
Diagnosis was confirmed by a study psychiatrist (SJ), 
using a structured instrument (Mini-International Neuro-
psychiatric Interview).13 Inclusion criteria also required 
people with psychosis to be antipsychotic naive, 
antipsychotic free for at least 6 weeks, or minimally 
treated (receiving antipsychotic medication for 2 weeks 
or less).
Healthy control participants were recruited through 
local media from the same geographical area as the 
patients. Inclusion criteria for controls were: no personal 
history of psychiatric illness (assessed using Mini-
International Neuropsychiatric Interview) and no con-
current psycho tropic medication (through self-report).
Exclusion criteria for all participants were: history of 
substantial head trauma, dependence on illicit substances, 
medical comorbidity (other than minor illnesses), and 
contraindications to scanning (such as pregnancy). 
Symptoms were measured using PANSS, with raters 
blinded to imaging results. Age, gender, and ethnicity 
(white or non-white) were also recorded.
Research in context
Evidence before this study
Animal and drug models of psychosis have suggested a link 
between cortical glutamate dysfunction and dopamine 
dysregulation in schizophrenia. We searched PubMed for 
studies published from database inception until July 3, 2018 
that used neuroimaging to investigate both dopamine and 
glutamate function in psychosis. Search terms were 
“dopamine”, “glutamate”, and “psychosis”. Previous studies 
have found a negative correlation between hippocampal 
glutamate and striatal dopamine measures in individuals 
at risk of psychosis. In healthy controls, a positive correlation 
between anterior cingulate cortex glutamate and striatal 
dopamine measures has been observed. To date, 
the relationship between cortical glutamate and striatal 
dopamine has not been directly examined in people with 
psychotic illness.
Added value of this study
Our study of individuals with a diagnosis of first-episode 
psychosis showed a negative correlation between anterior 
cingulate cortex glutamate concentration and striatal dopamine 
synthesis capacity, and that both measures related to PANSS were 
associated with PANSS positive symptom scores. To the best of 
our knowledge, this is the first study to demonstrate a 
relationship between dopaminergic and glutamatergic function 
and psychotic symptoms in individuals with psychosis.
Implications of all the available evidence
The dopaminergic and glutamatergic systems seem to be 
correlated in patients with first-episode psychosis. The 
combination of multimodal imaging techniques with 
longitudinal randomised treatment designs has the potential to 
advance our understanding in this area.
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Ethical permission was given by East of England–
Cambridge East Ethics Committee, and the 
Administration of Radioactive Substances Advisory 
Committee. All participants provided written informed 
consent to participate.
PET imaging acquisition and analysis
All participants were asked not to eat or drink 
(except water), and to refrain from alcohol for 12 h before 
scan. Imaging data were obtained on a Siemens Biograph 
6 HiRez PET scanner (Erlangen, Germany) in 3D mode. 
1 h before scan, participants received 400 mg entacapone, 
a peripheral catechol-o-methyl-transferase inhibitor, and 
150 mg carbidopa, a peripheral aromatic acid decarbo-
xylase inhibitor, to prevent formation of radiolabelled 
metabolites that might cross the blood–brain barrier. 
Participants were positioned in the scanner with the 
orbitomeatal line parallel to the transaxial plane of 
the tomograph. Head position was marked and 
monitored; movement was minimised with a head strap. 
After acquiring a CT scan for attenuation correction, 
approximately 150 MBq of ¹⁸F-DOPA was administered 
by bolus intravenous injection 30 s after start of PET 
imaging. PET data were acquired in 32 frames of 
increasing duration over the 95 min scan (frame intervals: 
8 × 15 s, 3 × 60 s, 5 × 120 s, 16 × 300 s). Our primary 
measure was striatal influx constant (Kicer) for the whole 
striatum.
Correction for head movement during scan was done 
by a mutual information algorithm, as described in 
previous publications.14,15 SPM 816 was used to automatically 
normalise a tracer-specific 18F-DOPA template together 
with the striatal brain atlas as defined by Martinez and 
colleagues.17 Kicer was calculated using the Patlak–Gjedde 
graphical approach adapted for a reference tissue input 
function, used in previous studies by our group.13,18
MRS acquisition
All scans were acquired on a General Electric (Milwaukee, 
WI, USA) Signa HDxt 3 Tesla MRI scanner. Internal 
localiser scans were used to establish the anterior 
commissure–posterior commissure line and interhemi-
spheric angle. Two structural scans were obtained: an 
axial 2D T2-weighted fast-spin echo scan and an axial fast 
fluid-attenuated inversion recovery. For the voxel place-
ments, 3D coronal inversion recovery-prepared spoiled-
gradient echo scans were acquired, followed by auto 
prescans for optimisation of water suppression and 
shimming. Proton MRS spectra were acquired for 
the anterior cingulate region-of-interest (right–left 
20 mm × anterior–posterior 20 mm × superior–inferior 
20 mm). The placement of the anterior cingulate voxel 
was based on the midline sagittal localiser with the centre 
of the 20 mm × 20 mm × 20 mm voxel placed 13 mm above 
the anterior portion of the genu of the corpus callosum, 
perpendicular to the anterior commissure–posterior 
commissure line to minimise inclusion of white matter 
and cerebrospinal fluid (CSF, see figure 1). Finally, proton 
MRS spectra (Point RESolves Spectroscopy, echo time 
30 ms, repetition time 2 s) were obtained through the 
PROton Brain Examination sequence by General Electric, 
which includes water suppression.
MRS analysis
All water-scaled metabolites were analysed with an 
LC-model 6.3-I0 to estimate concentrations of 
glutamate.¹⁹ Spectra were inspected visually and 
metabolite analyses were restricted to spectra with line 
width (full-width at half-maximum) ≤0∙1 ppm, 
Cramér–Rao lower bounds for glutamate ≤20%, and 
signal to noise ratio ≤5. Corrections were applied to 
account for relative distribution of CSF within the 
anterior cingulate. In-house scripts were used to identify 
the relative distribution of white matter, grey matter, and 
CSF in the 2 cm² voxel prescribed to the anterior 
cingulate. The following correction was subsequently 
applied to correct for CSF content within the 2 cm² voxel; 









Figure 1: Voxel placement for measurement of anterior cingulate cortex glutamate concentrations
Mcorr=
M([WM + GM] × 1·22 + [CSF × 1·55])
WM + GM
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Sample size and power calculation
We determined the minimum sample size required to 
test our primary hypothesis (that there was an inverse 
relationship between dopamine and glutamate 
measures). As no previous studies have examined the 
relationship between dopaminergic and glutamate 
measures in vivo, in patients with psychosis, we used the 
one previous study of this relationship in people at risk of 
psychosis to estimate effect size. This study found a 
relationship between these measures, with an R²=0∙28 
and sample size of 16.20 To be conservative, we therefore 
powered the study to detect an R² of at least 0∙25. By use 
of this effect size, the power calculation indicated a 
sample size of 26 would have more than 80% power to 
detect a significant relationship between these variables, 
at p<0∙05 (two-tailed).
Statistical analysis
All statistical analysis was done by use of R version 3.3.2 
and significance set at p<0∙05 (two-tailed). Our primary 
analysis fitted a linear regression model with striatal 
dopamine synthesis capacity as the dependent variable, 
and anterior cingulate cortex glutamate concentrations 
as predictor. Given the possible effects of age,21 sex,22,23 
and ethnicity24 on imaging measures, we did secondary 
exploratory analyses that adjusted for these demographic 
factors. Additionally, as antipsychotic treatment could 
influence imaging measures and symptom severity 
ratings25,26 we added medication status at time of scan 
(on antipsychotic treatment or drug free) to this model. 
The same approach was used to investigate whether the 
relationship between imaging measures and symptom 
severity measures was influenced by these factors.
Role of the funding source
The study funders had no role in study design, collection, 
analysis, or interpretation of data or writing of the 
manuscript. The corresponding author had full access to 
all data for the study, and made the decision to submit for 
publication.
Results
29 patients completed the study but data from one 
participant were excluded owing to poor quality proton 
MRS spectra on visual inspection, leaving 28 patients in 
the analysis. Demographic details are given in the table; 
there were no clinically significant differences in age, 
gender, or ethnicity between patient and control groups. 
79% of the patients were men, and the mean age was 
25∙4 years (table). Mean total PANSS score was 
69∙2 (SD 19∙1), and 25 (89%) of the 28 patients were not 
taking antipsychotics at the time of scanning (of whom, 
12 [48%] had never taken antipsychotics).
Of the three patients taking antipsychotics at time 
of scan (minimally treated, for less than 2 weeks), 
one patient was taking amisulpride 150 mg once daily, one 
patient was taking amisulpride 200 mg once daily, and 
one patient was taking risperidone 2 mg once daily. 
Two patients were taking clonazepam 0∙5 mg twice daily, 
and one patient was taking an antidepressant medication 
(sertraline 150 mg once daily) at time of scan. When 
patients were taking treatment, there was no change in 
medication status between PET and MRS scans.
Patients (n=28) Controls (n=20)
Sex
Male 22 (79%) 13 (65%)
Female 6 (21%) 7 (35%)






Antipsychotic naive 12 (43%) NA
Minimally treated† 3 (11%) NA
Antipsychotic free 13 (46%) NA
Injected radiolabel activity 
(MBq)
143∙4 (7∙5) 153∙2 (12∙9)
Duration of illness (months)* 23 (28∙25) NA
PANSS
Positive 18∙4 (6∙6) NA
Negative 15∙4 (6∙1) NA
General 35∙1 (9∙0) NA
Total 69∙2 (19∙1) NA
Data are expressed as n (%) or mean (SD), unless specified. PANSS=Positive and 
Negative Syndrome Scale. *Median (IQR). NA=not applicable. †Receiving 
antipsychotic medication for 2 weeks or less. 
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Median time between PET and MRI scans was 6 days 
(IQR 2·75–24·25). Some of the PET, but not MRS, data 
have previously been reported as part of a different 
analysis.13
15 people met ICD-10 criteria for schizophrenia, one for 
schizophreniform disorder, 11 for bipolar affective dis-
order, and one for severe depression with psychotic 
features.
We observed an inverse relationship between striatal 
dopamine synthesis capacity and anterior cingulate 
glutamate concentrations (β −1∙71 × 10−⁴, SE 7∙63 × 10−⁵, 
p=0∙03, R²=0∙16, r=−0∙40) in patients, but not in indivi-
duals in the control group (β 1∙15 × 10−⁴, SE 1∙30 × 10−⁴, 
p=0∙39, R²=0∙04, r=0∙20; see figure 2). To establish 
whether the relationship observed in patients could be 
influenced by confounding variables, we fitted additional 
regression models, including these variables. In a 
model including glutamate, age, gender, and ethnicity, 
glutamate concentrations remained predictive of 
striatal dopamine synthesis capacity (β −2∙03 × 10−⁴, 
SE 7∙70 × 10−⁵, p=0∙015). When medication status was 
included in this model, gluta mate concentration remained 
a significant predictor (β −1∙79 × 10−⁴, SE 8∙12 × 10−⁵, 
p=0∙039), indicating that antipsychotic medication did 
not explain the relationship. For the individuals in the 
control group, including demographic variables did not 
have any effect on the dopamine–glutamate relationship, 
which remained non-significant (β 1∙38 × 10−⁴, 
SE 1∙45 × 10−⁴, p=0∙36).
When Glx, rather than glutamate, was used as a 
predictor variable in patients, the relationship with 
dopamine was no longer significant in the initial model 
(β −9∙6 × 10−⁵, SE 6∙4 × 10−⁵, p=0∙14). The relationship 
was significant when demographic variables were 
included (β −1∙6 × 10−⁴, SE 6∙8 ×  10−⁵, p=0∙029), 
although not when medication status was also added 
(β −1∙4 × 10−⁵, SE 6∙9 × 10−⁵, p=0∙050). For individuals in 
the control group, the relationship was not significant 
for any of the models (p=0∙46–0∙55). A post-hoc 
analysis showed that there was a significant difference 
in the strength of the bivariate dopamine–glutamate 
correlation between patients and controls (Fisher’s 
r-to-z: z=−2∙01, p=0∙04).
We next explored the relationship between dopamine 
and PANSS-positive psychotic symptoms. The initial 
model showed a direct relationship between striatal 
dopamine synthesis capacity and PANSS-positive 
symptom severity rating (β 2546, SE 1217, p=0∙046, 
R²=0∙14; figure 3). Addition of age, gender, and ethnicity 
weakened the relationship between dopamine synthesis 
capacity and positive symptoms (β 2099, SE 1180, 
p=0∙089). Adding medication status slightly strengthened 
the relationship between dopamine and symptoms, 
although it remained non-significant (β 2269, SE 1266, 
p=0∙087). We then examined the relationship between 
cortical glutamate and symptoms. The initial model with 
glutamate concen trations as the sole predictor of PANSS 
positive scores showed an inverse relationship (β −1∙16, 
SE 0∙51, p=0∙03, R²=0∙16). The inclusion of age, gender, 
and ethnicity strengthened the relationship between 
glutamate concentrations and positive symptoms 
(β −1∙40, SE 0∙44, p=0∙0045; figure 3). Adding medication 
status had no marked effect on the relationship between 
glutamate and symptoms (β −1∙52, SE 0∙47, p=0∙0037).
There were no significant relationships between 
negative symptom severity ratings and either glutamate 
or dopamine measures (glutamate p=0∙37, Kicer, p=0∙09). 
A post-hoc analysis showed that there were no 
statistically significant differences between patients and 
controls in mean striatal Kicer (t[46]=−0∙37, p=0∙71) or 

















Anterior cingulate cortex glutamate concentration (institutional units)
0
0 20·00
Figure 3: Relationships between positive psychotic symptoms and (A) striatal dopamine synthesis capacity*, and (B) anterior cingulate cortex glutamate concentrations†
The red line represents a linear regression where symptom scores are the dependent variable and the imaging measure is the independent variable.*p=0∙046. †p=0∙03.
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Discussion
Our main finding is that an inverse relationship exists 
between anterior cingulate cortex glutamate concen-
trations and striatal dopamine synthesis capacity in 
people with first-episode psychosis. Furthermore, 
PANSS-positive symptoms were directly related to 
dopamine synthesis capacity and inversely related to 
anterior cingulate glutamate concentrations.
Preclinical studies have shown that N-methyl-D 
aspartate receptor blockade, induced using ketamine, 
increases striatal dopamine concentrations.27 Evidence 
from PET studies in humans also shows that N-methyl-D 
aspartate receptor blockade by ketamine results in 
dopamine release to a challenge, as measured by the 
displacement of D2 and D3 ligands.28,29 Furthermore, 
hippocampal glutamate concentrations have been found 
to be inversely related to striatal dopamine synthesis 
capacity in people at risk of psychosis.20 Thus, several lines 
of evidence indicate that alterations in cortical glutamate 
signalling could lead to disinhibition in striatal dopamine 
synthesis capacity. Our results extend these previous 
findings to show, for the first time as far as we are 
aware, an inverse relationship between cortical glutamate 
and striatal dopamine in people with psychosis. This 
correlation indicates that, in individuals with psychosis, 
those with lower cortical glutamate concentrations show 
greater striatal dopamine synthesis capacity. It is also 
possible that the observed relationship is due to striatal 
dopamine function driving medial prefrontal cortex 
glutamate function. Longitudinal studies are now required 
to establish the direction of causality.
Our study extends previous studies by testing the 
relationship between psychotic symptoms, striatal dopa-
minergic measures, and prefrontal cortex glutamatergic 
measures, in the same patients. Our findings, taken with 
those in patients at risk of psychosis,20 are consistent with 
the hypothesis that alterations in cortical glutamatergic 
concentrations underlie subcortical dopamine dysregu-
lation and the development of psychotic symptoms. As 
above, longitudinal studies are now required to establish 
the direction of causality.
Previous MRS studies have either not shown a 
relationship between glutamate concentrations or the 
glutamine to glutamate ratio in the anterior cingulate and 
positive symptoms in early schizophrenia, or have not 
tested the relationship.7 Our finding of a direct 
relationship between dopamine synthesis capacity and 
symptoms of psychosis adds to previous findings in 
people with prodromal and psychotic disorders in some,4,5 
but not all studies.30 In studies that did not find a 
relationship, several factors might explain the discrepant 
findings. Firstly, the sample sizes in several studies were 
fairly modest, and they might have lacked the power to 
detect relationships. Second, many of them included 
people with chronic and stable illness, receiving 
antipsychotic treatment, which is likely to have reduced 
symptom severity.
Direct glutamatergic projections from the prefrontal cortex 
to the midbrain have an excitatory influence on 
mesostriatal dopamine neurons, and enhance dopamine 
release, whereas indirect pathways involving GABA-ergic 
interneurons have the opposite effect.8,9 If the direct 
pathways play a larger role, then reduced glutamatergic 
activity will be accompanied by lower striatal dopaminergic 
signalling, whereas if indirect pathways dominate, then 
lower glutamatergic signalling will disinhibit mesostriatal 
dopamine neurons, and lead to greater dopaminergic 
activity. We found a negative correlation in patients, which 
suggests that the indirect pathway projections onto 
dopamine neurons pre-dominate in psychosis. However, it 
is important to note that it is not yet possible to distinguish 
the function of these projec tions in vivo in humans, and, 
thus, this is a speculative interpretation. Translational 
studies in animals with the same MRS and PET imaging 
approaches used in human studies are needed to explore 
the circuit level implications of our findings.
We did not find a relationship between dopamine 
synthesis capacity and glutamate concentrations in 
controls. The only other published study in healthy 
volunteers showed a negative relationship between 
striatal dopamine synthesis capacity and glutamate 
concentrations in the dorsolateral prefrontal cortex.10 
This discrepancy could be due to differences in the 
regions of the brain investigated, as the study by Gleich 
and colleagues10 examined glutamate concentrations in 
the dorsolateral prefrontal cortex, whereas we investi-
gated the anterior cingulate cortex. Taken together, these 
findings could suggest that the coupling between cortical 
glutamate concentration and striatal dopamine synthesis 
capacity is stronger in the dorsolateral prefrontal cortex 
than the anterior cingulate cortex.
Acute ketamine administration increases both dopa-
mine and glutamate concentrations in animal27 and 
human studies28,29,31 although negative results have also 
been reported.32 One interpretation of these findings is that 
dopamine synthesis capacity and glutamate concentrations 
are directly related to each other, in contrast to our findings. 
Ketamine’s acute effects on increasing dopamine 
concentrations are more marked in cortical regions than 
the striatum,27 whereas cortical dopamine release has been 
shown to be lower in patients with schizophrenia 
compared with controls.33 Thus our findings of an inverse 
relationship between glutamate concentration and 
dopamine synthesis capacity in patients with psychosis, in 
contrast to what is predicted from acute studies of 
ketamine’s effects on these systems, add to the evidence 
that acute ketamine is not an exact model of the 
pathophysiology of psychosis, and highlights the need for 
further studies of both the dopamine and glutamate 
systems in people with psychosis.
In contrast to other studies,6,13 we found no significant 
differences in striatal Kicer or anterior cingulate glutamate 
concentrations between patients and controls. In addition 
to the possibility of a type II error, a potential reason for 
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this difference to previous studies is that our cohort 
includes patients with both responsive and non-
responsive forms of illness. In the responsive forms of 
illness, findings indicate increased dopamine concen-
trations and unaltered glutamate concentrations, whereas 
in the non-responsive forms of illness, findings indicate 
unaltered dopamine concentrations and increased 
glutamate concentrations.15
A strength of the current study is acquiring multimodal 
imaging in a comparatively large sample of people 
with first-episode psychosis, who were predominantly 
antipsychotic free or naive. Scans were taken in close 
temporal proximity, with a median of 6 days between 
scans.
A potential limitation is that abstinence from substance 
use before imaging was not confirmed with urine or 
similar drug tests for all scans, although we excluded 
substance dependence or abuse through clinical 
assessment. Thus, it is possible that recreational use of 
substances influenced our results; however, the effects of 
recreational substance use on dopamine synthesis 
capacity are unclear.34
Limitations also include the fact that three people had 
received a short course of treatment with antipsychotic 
medication. Acute treatment with a dopamine antagonist 
might have altered both the dopamine and glutamate 
measures. There is only one published longitudinal study 
in humans with psychosis examining the effects of 
antipsychotics on dopamine synthesis capacity, which 
suggests a decrease in dopamine synthesis capacity in the 
caudate and putamen with subchronic (5 weeks) 
haloperidol treatment.25 Thus, treatment could have 
reduced dopamine synthesis capacity in the three 
participants taking medication. However, cross-sectional 
studies in patients taking antipsychotics have shown 
dopamine synthesis is increased relative to controls.3 
There is no consensus regarding the effects of dopamine 
blocking agents on glutamate concentrations as measured 
using MRS,26 with four of eight studies showing no 
significant effect of treatment on glutamate concentrations 
and four showing a significant decrease in Glx in left 
temporal lobe, frontal lobe, and thalamus, and glutamate 
in right striatum.26 Taken together, these findings suggest 
that if antipsychotic treatment were to influence the 
dopamine–glutamate relationship, it would be to reduce 
the inverse relationship we observe. As such, if anti-
psychotics are having an effect, this would not explain our 
findings. Moreover, the relationship between measures 
remained significant when medication status was 
accounted for in the analysis, suggesting that antipsychotic 
effects do not explain our findings. Nevertheless, further 
studies would be useful to confirm this. Although there is 
no in-vivo evidence of the effects of benzodiazepines and 
sertraline on either imaging measure, it is conceivable 
that these compounds had an effect, though the small 
number of patients taking these medictions suggests this 
would not markedly affect our primary findings.
It should also be recognised that the glutamate signal 
at 3T includes some contribution from glutamine, 
about 10–15%, and scanning at higher field strengths is 
required to more fully separate glutamate and glutamine. 
Further specific limitations include the relatively low 
spatial resolution of the imaging techniques, and the 
inability to differentiate intracellular and extracellular 
glutamate concentrations. A limitation of our study, and 
the field in general, is that, at the time of writing, it is 
not possible to delineate the precise mechanistic 
relationship between cortical glutamate and dopamine 
in vivo. 
Notwithstanding the caveats discussed above, our 
findings suggest glutamatergic and dopaminergic 
systems are closely related in patients with psychosis, in 
line with preclinical models, and support further studies 
to test the effect of modulating cortical glutamate in the 
treatment of psychosis.
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